The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...